T. Rowe Price Associates’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $328M | Buy |
4,090,968
+1,964,213
| +92% | +$162M | 0.04% | 342 |
|
|
2025
Q4 | $181M | Buy |
2,126,755
+1,267,918
| +148% | +$104M | 0.02% | 494 |
|
|
2025
Q3 | $66.8M | Sell |
858,837
-1,255
| -0.1% | -$98.1K | 0.01% | 709 |
|
|
2025
Q2 | $67.3M | Buy |
860,092
+398
| +0% | +$29.7K | 0.01% | 655 |
|
|
2025
Q1 | $62.3M | Sell |
859,694
-2,438,028
| -74% | -$175M | 0.01% | 655 |
|
|
2024
Q4 | $244M | Sell |
3,297,722
-244,061
| -7% | -$17.1M | 0.03% | 386 |
|
|
2024
Q3 | $234M | Sell |
3,541,783
-3,793,955
| -52% | -$276M | 0.03% | 407 |
|
|
2024
Q2 | $678M | Buy |
7,335,738
+819,478
| +13% | +$72.6M | 0.08% | 213 |
|
|
2024
Q1 | $623M | Buy |
6,516,260
+2,390,137
| +58% | +$201M | 0.08% | 239 |
|
|
2023
Q4 | $315M | Buy |
4,126,123
+842,848
| +26% | +$58.6M | 0.04% | 331 |
|
|
2023
Q3 | $227M | Buy |
3,283,275
+2,469,870
| +304% | +$198M | 0.03% | 366 |
|
|
2023
Q2 | $76.7M | Sell |
813,405
-18,108
| -2% | -$1.57M | 0.01% | 586 |
|
|
2023
Q1 | $68.8M | Buy |
831,513
+21,079
| +3% | +$1.66M | 0.01% | 597 |
|
|
2022
Q4 | $60.5M | Buy |
810,434
+3,968
| +0.5% | +$306K | 0.01% | 615 |
|
|
2022
Q3 | $66.6M | Sell |
806,466
-448
| -0.1% | -$43.1K | 0.01% | 574 |
|
|
2022
Q2 | $76.7M | Sell |
806,914
-83,655
| -9% | -$8.66M | 0.01% | 739 |
|
|
2022
Q1 | $105M | Sell |
890,569
-54,134
| -6% | -$6.07M | 0.01% | 718 |
|
|
2021
Q4 | $122M | Sell |
944,703
-30,418
| -3% | -$3.55M | 0.01% | 705 |
|
|
2021
Q3 | $110M | Sell |
975,121
-15,517
| -2% | -$1.77M | 0.01% | 733 |
|
|
2021
Q2 | $103M | Sell |
990,638
-10,757
| -1% | -$1.01M | 0.01% | 773 |
|
|
2021
Q1 | $83.8M | Sell |
1,001,395
-78,254
| -7% | -$6.62M | 0.01% | 827 |
|
|
2020
Q4 | $98.5M | Sell |
1,079,649
-128,172
| -11% | -$10.6M | 0.01% | 728 |
|
|
2020
Q3 | $96.4M | Buy |
1,207,821
+25,864
| +2% | +$2.02M | 0.01% | 665 |
|
|
2020
Q2 | $81.7M | Sell |
1,181,957
-95,335
| -7% | -$6.78M | 0.01% | 694 |
|
|
2020
Q1 | $80.3M | Buy |
1,277,292
+105,894
| +9% | +$7.64M | 0.01% | 639 |
|
|
2019
Q4 | $91.1M | Sell |
1,171,398
-18,708
| -2% | -$1.46M | 0.01% | 694 |
|
|
2019
Q3 | $87.2M | Buy |
1,190,106
+23,871
| +2% | +$1.68M | 0.01% | 661 |
|
|
2019
Q2 | $71.8M | Sell |
1,166,235
-1,041
| -0.1% | -$62.9K | 0.01% | 757 |
|
|
2019
Q1 | $74.4M | Buy |
1,167,276
+69,225
| +6% | +$3.95M | 0.01% | 722 |
|
|
2018
Q4 | $56.1M | Buy |
1,098,051
+16,707
| +2% | +$845K | 0.01% | 781 |
|
|
2018
Q3 | $62.8M | Sell |
1,081,344
-30,366
| -3% | -$1.49M | 0.01% | 828 |
|
|
2018
Q2 | $53.9M | Buy |
1,111,710
+4,866
| +0.4% | +$227K | 0.01% | 871 |
|
|
2018
Q1 | $51.5M | Buy |
1,106,844
+3,900
| +0.4% | +$169K | 0.01% | 858 |
|
|
2017
Q4 | $41.4M | Sell |
1,102,944
-6,300
| -0.6% | -$231K | 0.01% | 934 |
|
|
2017
Q3 | $40.4M | Sell |
1,109,244
-67,644
| -6% | -$2.58M | 0.01% | 935 |
|
|
2017
Q2 | $46.4M | Sell |
1,176,888
-44,964
| -4% | -$1.64M | 0.01% | 849 |
|
|
2017
Q1 | $38.3M | Sell |
1,221,852
-9,543
| -0.8% | -$299K | 0.01% | 905 |
|
|
2016
Q4 | $38.5M | Buy |
1,231,395
+39,525
| +3% | +$1.28M | 0.01% | 904 |
|
|
2016
Q3 | $47.9M | Sell |
1,191,870
-666,450
| -36% | -$25.1M | 0.01% | 820 |
|
|
2016
Q2 | $61.8M | Buy |
1,858,320
+34,140
| +2% | +$1.17M | 0.01% | 702 |
|
|
2016
Q1 | $53.6M | Sell |
1,824,180
-3,870
| -0.2% | -$107K | 0.01% | 745 |
|
|
2015
Q4 | $48.1M | Sell |
1,828,050
-1,500
| -0.1% | -$39K | 0.01% | 778 |
|
|
2015
Q3 | $43.4M | Sell |
1,829,550
-3,600
| -0.2% | -$86.9K | 0.01% | 816 |
|
|
2015
Q2 | $43.5M | Buy |
1,833,150
+14,940
| +0.8% | +$337K | 0.01% | 889 |
|
|
2015
Q1 | $43.2M | Buy |
1,818,210
+67,200
| +4% | +$1.51M | 0.01% | 890 |
|
|
2014
Q4 | $37.2M | Buy |
1,751,010
+37,860
| +2% | +$761K | 0.01% | 936 |
|
|
2014
Q3 | $29.2M | Buy |
1,713,150
+10,200
| +0.6% | +$161K | 0.01% | 1012 |
|
|
2014
Q2 | $24.4M | Sell |
1,702,950
-48,540
| -3% | -$658K | 0.01% | 1062 |
|
|
2014
Q1 | $21.7M | Sell |
1,751,490
-360,120
| -17% | -$4.16M | ﹤0.01% | 1084 |
|
|
2013
Q4 | $23.1M | Sell |
2,111,610
-489,960
| -19% | -$5.52M | 0.01% | 1062 |
|
|
2013
Q3 | $30.2M | Sell |
2,601,570
-45,382,686
| -95% | -$531M | 0.01% | 976 |
|
|
2013
Q2 | $537M | Buy |
+47,984,256
| New | +$568M | 0.14% | 185 |
|
Other funds holding EW
VCM
VPM
T. Rowe Price Associates's EW Position: Q1 2026 in Review
T. Rowe Price Associates increased its Edwards Lifesciences (EW) stake by 92% in Q1 2026, buying an estimated $162M and bringing the position to 4,090,968 shares worth $328M. The position accounts for 0.04% of the portfolio, ranked #342.
T. Rowe Price Associates first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $678M in Q2 2024. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- T. Rowe Price Associates held 4,090,968 shares of Edwards Lifesciences worth $328M as of Q1 2026.
- T. Rowe Price Associates bought 1,964,213 Edwards Lifesciences shares in Q1 2026, an estimated $162M.
- Edwards Lifesciences made up 0.04% of T. Rowe Price Associates's portfolio in Q1 2026, its #342 holding.
- T. Rowe Price Associates first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
- T. Rowe Price Associates's Edwards Lifesciences position peaked at $678M in Q2 2024.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.